Reviews

Compounded GLP-1 medications are patient-specific medication prescribed by a licensed healthcare provider based on a medical assessment and compounded in a 503(a) Compounding Pharmacy or 503(b) Outsourcing Facility. The Shot Spot exclusively works with licensed compounding pharmacies in the United States.

Compounded medications do not undergo pre-market review or an FDA-approval process. They may differ in efficacy, safety, risk, and side-effect profiles from commercially available or FDA-approved drugs. Data from clinical trials on FDA-approved medications should not be used to make assessments related to compounded medications.

The Shot spot does not offer the following FDA-approved medications: Rybelsus®, Ozempic®, Wegovy®, Zepbound® or Mounjaro®. If you wish to recieve one of these medications, speak to your local healthcare provider.

Ozempic® (semaglutide), Wegovy® (semaglutide), and Generic Liraglutide are not compounded. Ozempic® and Generic Liraglutide are FDA-approved for type 2 diabetes treatment but may be prescribed off-label for weight loss at a healthcare provider's discretion. Wegovy® is FDA-approved for weight loss. Ozempic® and Wegovy® are the registered trademarks of Novo Nordisk A/S. The Shot Spot is not affiliated with or endorsed by Novo Nordisk A/S.

Novo Nordisk Inc. is the only company in the United States with FDA-approved products containing semaglutide, identified under the trade names Rybelsus®, Ozempic®, and Wegovy®. Novo Nordisk Inc. does not sell semaglutide to any entities for use in compounding.

Eli Lilly and Company is the only company in the United States with FDA-approved products containing tirzepatide, identified under the trade names Zepbound® and Mounjaro®. Eli Lilly and Company does not sell tirzepatide to any entities for use in compounding.